Abstract
This study aimed to investigate the safety and feasibility of intracoronary injection of human umbilical cord mesenchymal stem cell to the very old patients with coronary chronic total occlusion. 15 consecutive patients received mesenchymal stem cells from human umbilical cord in epicardial coronary artery supplying collateral circulation. The patients were randomly allocated to low-dose 3x106, mid-dose 4x106 and high-dose 5x106 groups. 99mTc single photon emission computed tomography images were obtained at 12 and 24 months. During the 24 month study period, no cases of major cardiac adverse events were reported. None of the patients had coronary care unit admissionshospitalizationsfurther coronary revascularizationacute myocardial infarction and death. The patients had a significant reduction of the infarct size and a remarkable rise in left ventricular ejection fraction with respect to secondary outcomes. This study suggested that stem cell transplantation was safe and feasible. The cells can be utilized to improve in the degree of ischemic myocardium, decrease in the infarct size and rise in left ventricular ejection fraction.
Keywords: Chronic myocardial ischemia, elderly, human umbilical cord-derived mesenchymal stem cells, therapy.
Current Pharmaceutical Design
Title:Safety and Efficacy of Intracoronary Human Umbilical Cord-Derived Mesenchymal Stem Cell Treatment for Very Old Patients with Coronary Chronic Total Occlusion
Volume: 21 Issue: 11
Author(s): Xia Li, You-dong Hu, Yan Guo, Ying Chen, Dian-xuan Guo, Hua-lan Zhou, Feng-lin Zhang and Qing-na Zhao
Affiliation:
Keywords: Chronic myocardial ischemia, elderly, human umbilical cord-derived mesenchymal stem cells, therapy.
Abstract: This study aimed to investigate the safety and feasibility of intracoronary injection of human umbilical cord mesenchymal stem cell to the very old patients with coronary chronic total occlusion. 15 consecutive patients received mesenchymal stem cells from human umbilical cord in epicardial coronary artery supplying collateral circulation. The patients were randomly allocated to low-dose 3x106, mid-dose 4x106 and high-dose 5x106 groups. 99mTc single photon emission computed tomography images were obtained at 12 and 24 months. During the 24 month study period, no cases of major cardiac adverse events were reported. None of the patients had coronary care unit admissionshospitalizationsfurther coronary revascularizationacute myocardial infarction and death. The patients had a significant reduction of the infarct size and a remarkable rise in left ventricular ejection fraction with respect to secondary outcomes. This study suggested that stem cell transplantation was safe and feasible. The cells can be utilized to improve in the degree of ischemic myocardium, decrease in the infarct size and rise in left ventricular ejection fraction.
Export Options
About this article
Cite this article as:
Li Xia, Hu You-dong, Guo Yan, Chen Ying, Guo Dian-xuan, Zhou Hua-lan, Zhang Feng-lin and Zhao Qing-na, Safety and Efficacy of Intracoronary Human Umbilical Cord-Derived Mesenchymal Stem Cell Treatment for Very Old Patients with Coronary Chronic Total Occlusion, Current Pharmaceutical Design 2015; 21 (11) . https://dx.doi.org/10.2174/1381612821666141126100636
DOI https://dx.doi.org/10.2174/1381612821666141126100636 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Hypertension in Peripheral Arterial Disease
Current Pharmaceutical Design Amiloride Alleviates Neurological Deficits Following Transient Global Ischemia and Engagement of Central IL-6 and TNF-α Signal
Current Molecular Medicine Cell-Based Therapy to Promote Angiogenesis in the Brain Following Ischemic Damage
Current Vascular Pharmacology Fish Oil Supplementation: A Matter of DHA Enzymatic/Non-Enzymatic Oxidation Balance?
Current Nutrition & Food Science Realising Heart Regeneration
Current Tissue Engineering (Discontinued) Modulating Poly (ADP-Ribose) Polymerase Activity: Potential for the Prevention and Therapy of Pathogenic Situations Involving DNA Damage and Oxidative Stress
Current Pharmaceutical Biotechnology Chemotherapeutic Options for Colorectal Cancer Patients with Cardiovascular Diseases.
Reviews on Recent Clinical Trials Oxytocin - A Multifunctional Analgesic for Chronic Deep Tissue Pain
Current Pharmaceutical Design Mesenchymal Stem Cells: Promising for Myocardial Regeneration?
Current Stem Cell Research & Therapy Nanomedicine: Magnetic Nanoparticles and their Biomedical Applications
Current Medicinal Chemistry Free Radicals in Diseases and Potential Role of Phytoconstituents-A Cause with Emerging Importance
Current Chemical Biology Potentiating the Naturally Occurring Process for Repair of Damaged Heart
Current Pharmaceutical Design Rivaroxaban versus Clopidogrel for Peripheral Artery Disease: A Clinico-Economic Approach of the COMPASS Trial
Current Pharmaceutical Design Radix Astragali (Astragalus): Latest Advancements and Trends in Chemistry, Analysis, Pharmacology and Pharmacokinetics
Current Organic Chemistry Evidence-Based Percutaneous Closure of the Left Atrial Appendage in Patients with Atrial Fibrillation
Current Cardiology Reviews Exosomes and the Emerging Field of Exosome-Based Gene Therapy
Current Gene Therapy Is the Therapeutic Potential of Stem Cells for Myocardial Regeneration Limited by Proarrhythmic Effects?
Current Cardiology Reviews The Pathophysiological Basis of Carotid Baroreceptor Stimulation for the Treatment of Resistant Hypertension
Current Vascular Pharmacology Future Directions in the Treatment of Neuropathic Pain: A Review on Various Therapeutic Targets
CNS & Neurological Disorders - Drug Targets An Old Drug with a New Purpose: Cardiovascular Actions of Acetaminophen (Paracetamol)
Current Drug Targets - Cardiovascular & Hematological Disorders